QL Biopharm Announces Abstract on Novel Ultra Long-acting GLP-1RA to be Presented at EASD Annual Meeting 2024
– Abstract on data from a two-part phase 1c, multiple ascending dose study accepted for oral presentation – – New data highlighting the Company’s lead drug candidate ZT002 for obesity – Beijing, China, 3 September 2024 – Beijing QL Biopharmaceutical Co., Ltd. (“QL Biopharm”), a clinical stage biopharmaceutical company developing innovative biologic drugs for the […]